SciELO - Scientific Electronic Library Online

 
vol.44 issue4Anti dermatophytic therapy: prospects for the discovery of new drugs from natural productsClavulanic acid production by the MMS 150 mutant obtained from wild type Streptomyces clavuligerus ATCC 27064 author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Brazilian Journal of Microbiology

Print version ISSN 1517-8382

Abstract

WEINACKER, Daniel et al. Applications of recombinant Pichia pastoris in the healthcare industry. Braz. J. Microbiol. [online]. 2013, vol.44, n.4, pp.1043-1048. ISSN 1517-8382.  http://dx.doi.org/10.1590/S1517-83822013000400004.

Since the 1970s, the establishment and development of the biotech industry has improved exponentially, allowing the commercial production of biopharmaceutical proteins. Nowadays, new recombinant protein production is considered a multibillion-dollar market, in which about 25% of commercial pharmaceuticals are biopharmaceuticals. But to achieve a competitive production process is not an easy task. Any production process has to be highly productive, efficient and economic. Despite that the perfect host is still not discovered, several research groups have chosen Pichia pastoris as expression system for the production of their protein because of its many features. The attempt of this review is to embrace several research lines that have adopted Pichia pastoris as their expression system to produce a protein on an industrial scale in the health care industry.

Keywords : yeast; heterologous expression system; recombinant protein; production; scale up.

        · text in English     · English ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License